Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2X-121 Monotherapy and in Combination With Dovitinib in Advanced Solid Tumors
NCT05571969Phase 1Terminated
- Sponsor
- Allarity Therapeutics
- Start
- Mar 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of stenoparib in solid tumor (advanced stage) (6 arms), sponsored by Allarity Therapeutics. Primary endpoints: Maximum Tolerated Dose of 2X-121 Monotherapy at 14 days and Maximum Tolerated Dose of Dovitinib Given in Combination With 2X-121 at 14 days. Started Mar 2023; status: terminated.
02
Drugs
stenoparib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05571969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05571969.